Faeth Therapeutics (FTH) Operating Expenses (2020 - 2026)

Faeth Therapeutics (FTH) has reported Operating Expenses for 7 consecutive years, with $18.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 253.15% year-over-year to $18.4 million; the trailing twelve-month figure through Jun 2026 stood at $198.8 million (up 595.73% YoY), and the FY2025 full-year result was $22.3 million, down 31.66% from the prior year.
• Operating Expenses declined to $18.4 million in Q2 2026 per FTH's latest filing, from $170.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $170.6 million in Q1 2026 and bottomed at $4.9 million in Q3 2025.
• Historically, Operating Expenses has averaged $18.4 million across 5 years, with a median of $8.5 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Operating Expenses slumped 44.5% in 2023, then surged 2245.71% in 2026.
• Over 5 years, Operating Expenses stood at $13.0 million in 2022, then sank by 37.6% to $8.1 million in 2023, then gained by 1.62% to $8.3 million in 2024, then tumbled by 40.09% to $5.0 million in 2025, then jumped by 270.89% to $18.4 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $18.4 million, $170.6 million, and $5.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.